A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

NCT07251309 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperkalemia

Interventions

DRUG: WS016
DRUG: Placebo
DRUG: WS016
DRUG: Placebo
DRUG: WS016

Sponsor

Waterstone Pharmaceutical (Wuhan) Co., LTD.